We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
![Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies](https://www.ohe.org/wp-content/uploads/2023/01/Cancer_WellcomeCollection_landscape.jpg)
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
![Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies](https://www.ohe.org/wp-content/uploads/2020/08/Bridge-150x150.png)
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
![Access to OMPs](https://www.ohe.org/wp-content/uploads/2017/03/Access-to-OMPs.jpg)
New Guidelines for Economic Evaluation in Germany and the United Kingdom: Are We Any Closer to Developing International Standards?
![316 - NewGuidelines_Nov2008_BIG](https://www.ohe.org/wp-content/uploads/2014/08/316-NewGuidelines_Nov2008_BIG.jpg)